Ionis Pharmaceuticals Inc $ 61.41 -1.13 (-1.81%)
Warning! GuruFocus has detected 2 Severe warning signs with IONS. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for Ionis Pharmaceuticals Inc () from 1991 to Jan 21 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Ionis Pharmaceuticals stock (IONS) PE ratio as of Jan 21 2021 is 127.9. More Details
Ionis Pharmaceuticals PE Ratio (TTM) Historical Data
View and export this data going back to 1991. Start your Free Trial
Ionis Pharmaceuticals PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:EXEL NAS:IMMU NAS:ACAD NAS:ASND NAS:ALLO NAS:JAZZ NAS:RETA NAS:XLRN NAS:ADPT NAS:IOVA OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY
Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Ionis' broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).